Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.580
-0.040 (-0.87%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$491,849
Profits / Employee
-$1,081,343
Market Cap
78.18M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Gossamer Bio | 162 |
| Sangamo Therapeutics | 142 |
| Adicet Bio | 102 |
| PolyPid | 75 |
| eXoZymes | 32 |
| NeurAxis | 24 |
| Q32 Bio | 24 |
ATHE News
- 1 day ago - Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development - GuruFocus
- 1 day ago - Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study - Nasdaq
- 1 day ago - Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy - GlobeNewsWire
- 6 days ago - Alterity Therapeutics (ATHE) Shows Promising Results in Phase 2 Trial for MSA - GuruFocus
- 6 days ago - Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology - GlobeNewsWire
- 11 days ago - Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics (ATHE) Prepares for Phase 3 Trial After FDA Feedback - GuruFocus
- 4 weeks ago - Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program - GlobeNewsWire